Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATHA 
Athira Pharma Inc (ATHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ATHA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $0.4
Year Target Price $0.4
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.91% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.52M USD | Price to earnings Ratio - | 1Y Target Price 0.4 |
Price to earnings Ratio - | 1Y Target Price 0.4 | ||
Volume (30-day avg) 3 | Beta 3.03 | 52 Weeks Range 0.22 - 3.67 | Updated Date 06/30/2025 |
52 Weeks Range 0.22 - 3.67 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.54% | Return on Equity (TTM) -110.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -24035479 | Price to Sales(TTM) - |
Enterprise Value -24035479 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.31 | Shares Outstanding 39042400 | Shares Floating 25140602 |
Shares Outstanding 39042400 | Shares Floating 25140602 | ||
Percent Insiders 8.27 | Percent Institutions 45.52 |
Analyst Ratings
Rating 2 | Target Price 0.4 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Athira Pharma Inc
Company Overview
History and Background
Athira Pharma, Inc. (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Founded in 2011, it has focused on targeting HGF/MET pathway to treat neurological diseases. The company has faced clinical trial setbacks and leadership changes, impacting its trajectory.
Core Business Areas
- Neurological Therapeutics Development: Focuses on developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Key clinical programs revolve around small molecule therapeutics affecting the HGF/MET pathway.
Leadership and Structure
The leadership team includes executives with experience in drug development, clinical research, and business management. The company's organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Fosgonimeton: A small molecule designed to enhance the activity of the HGF/MET receptor system in the brain, intended to improve synaptic function and reduce neuroinflammation. Currently in clinical trials for Alzheimer's disease and other neurological conditions. Market share is speculative given it is in the clinical stage. Competitors include companies developing Alzheimer's treatments such as Biogen (BIIB), Eisai (ESAIY), and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive, with significant unmet medical needs. Advancements in understanding disease mechanisms and developing novel therapeutic approaches are driving innovation. Regulatory hurdles and clinical trial success rates are major challenges.
Positioning
Athira Pharma is positioned as a company developing novel small molecule therapeutics for neurodegenerative diseases, specifically targeting the HGF/MET pathway. Its competitive advantage lies in its unique approach, but it faces the challenge of clinical trial execution and validation of its mechanism of action.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease and related neurodegenerative diseases is estimated to be in the tens of billions of dollars globally. Athira's positioning relative to this TAM depends on the clinical success and market adoption of its lead candidate, Fosgonimeton. If successful, it could capture a significant portion of the market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting HGF/MET pathway
- Focused pipeline on neurodegenerative diseases
- Experienced management team
- Early-stage clinical data showing potential efficacy
Weaknesses
- High clinical trial risk
- Dependence on single lead compound (Fosgonimeton)
- Limited financial resources compared to larger pharmaceutical companies
- History of leadership changes and past controversies
Opportunities
- Successful clinical trial outcomes for Fosgonimeton
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisitions
- Breakthrough Therapy Designation from regulatory agencies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
- Negative publicity and reputational risk
Competitors and Market Share
Key Competitors
- BIIB
- ESAIY
- LLY
- ABBV
- Roche (ROG.SW)
Competitive Landscape
Athira faces significant competition from larger pharmaceutical companies with established positions in the neurodegenerative disease market. Its competitive advantage lies in its novel HGF/MET pathway approach, but it must demonstrate clinical efficacy and navigate regulatory hurdles to successfully compete.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical development progress and financing activities. The company's growth trajectory has been significantly impacted by clinical trial setbacks.
Future Projections: Future growth depends heavily on the clinical success of Fosgonimeton. Analyst estimates are highly variable and dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for Fosgonimeton, managing cash burn, and addressing past controversies.
Summary
Athira Pharma is a high-risk, high-reward clinical-stage biopharmaceutical company with a novel therapeutic approach for neurodegenerative diseases. Its success hinges on the clinical development of Fosgonimeton. The company needs to manage its cash burn effectively and demonstrate positive clinical outcomes to attract partnerships and ultimately succeed. A history of controversy and small market share make the stock particularly vulnerable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Athira Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-09-18 | President, CEO & Director Dr. Mark J. Litton M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.athira.com |
Full time employees 26 | Website https://www.athira.com | ||
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.